Ellen Mintz, Ph.D., M.S.

Dr. Ellen Mintz provides regulatory support and IND management for a complex portfolio of the investigational agents. She started with the Regulatory Affairs Branch in 2019 as an NCI Presidential Management Fellow and completed rotations with both the Agreement Coordination Group and the Drug Regulatory Group of the Branch. As an NCI Presidential Management Fellow, she also completed an external detail at HHS in the Office of the Assistant Secretary for Preparedness and Response. Dr. Mintz officially became a member of the Drug Regulatory Group in 2021.  

Dr. Mintz earned her Ph.D. in Experimental Pathology from the University of Virginia School of Medicine, where she developed and assessed tissue engineering based approaches for the treatment of skeletal muscle injuries. She also received a M.S. in Biological Sciences from California Polytechnic State University, San Luis Obispo. Her thesis focused on the role of the Wnt signaling pathway in stem cell reprogramming, supported in part by a research internship from the California Institute for Regenerative Medicine.